Drug intelligence / Profile preview

Liangxue Tuizi Formula

Development stage: Preclinical
Lead developer: First Affiliated Hospital of Henan University of Chinese Medicine
Administration: Oral

Overview

Liangxue Tuizi Formula is a Traditional Chinese Medicine (TCM) herbal decoction developed by The First Affiliated Hospital of Henan University of Chinese Medicine for the treatment of Henoch-Schönlein purpura (HSP) in children. It is specifically indicated for patients diagnosed with the 'blood-heat' syndrome, a TCM classification characterized by heat-induced vascular extravasation. The formula is designed to 'cool the blood' and resolve purpuric lesions. It has been the subject of metabolomics research to characterize its impact on urine metabolic profiles and to differentiate its therapeutic effects from other TCM syndromes like 'wind-heat'.

Other names: Liangxue Tuizi decoction

Beyond the preview

Go deeper on Liangxue Tuizi Formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liangxue Tuizi Formula.

Explore the full profile